China Pharma Seeks Up-to-1:50 Reverse Split and 8.0M-Share Equity Plan Increase
CPHI sits 60% above its 52-week low of $0.382 on light trading volume (0.1× avg).
Summary
China Pharma's preliminary proxy asks shareholders to authorize a reverse split of up to 1:50 to protect its NYSE American listing and to expand the 2010 incentive plan reserve by 8,034,800 shares. Both measures go to a vote at the December 22, 2026 annual meeting.
Key Events · Corporate Governance and Compliance · CPHI
-
Reverse Split Up to 1:50 Proposed
Shareholders will vote on amending the charter to combine shares at a ratio of up to 1:50, with the Board choosing the final ratio and effective time.
-
Listing Defense Cited
The proxy ties the split to NYSE American's low-selling-price rule and warns that if the proposal fails and a deficiency letter issues, the company may be unable to maintain its listing.
-
Equity Plan Reserve Jumps to 8.6M
Amendment No.4 would raise the 2010 Long-Term Incentive Plan reserve by 8,034,800 shares, from 569,600 to 8,603,800 shares; 48,200 restricted shares were outstanding and no options were outstanding as of the proxy date.
-
Prior 1-for-10 Split in April 2025
The company completed a 1-for-10 reverse split on April 15, 2025; a new split within two years adds to the cumulative ratio the exchange tracks.
Analysis · CPHI · Life Sciences
For a $0.61 stock, two proposals carry real weight. The reverse split authorization of up to 1:50 is explicitly framed as a defense against NYSE American's low-selling-price rule, and the proxy warns that failing to approve it could cost the company its listing. The equity plan amendment would lift the reserve from 569,600 to 8,603,800 shares — roughly 8.0 million new shares available for awards, large relative to the current share base and representing meaningful future dilution if granted. Both are shareholder votes at the December 22, 2026 annual meeting, not yet effective; the Board can decline to implement the split even if approved.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPHI was trading at $0.61 on NYSE in the Life Sciences sector, with a market capitalization of approximately $26.9M. The 52-week trading range was $0.38 to $19.19. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.